Kangmei Pharmaceutical Overview
- Founded
-
1997
- Status
-
Public
- Employees
-
6,371
- Stock Symbol
-
600518
- Investments
-
2
- Share Price
-
$0.25
- (As of Friday Closing)
Kangmei Pharmaceutical General Information
Description
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the manufacturing, research and marketing of herbal medicine and chemical raw materials.
Contact Information
- Changchun middle road
- Puning, Guangdong 515300
- China
Kangmei Pharmaceutical Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.25 | $0.25 | $0.24 - $0.40 | 13.9B | 56.7M | -$0.03 |
Kangmei Pharmaceutical Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 3,657,331 | 4,139,970 | 11,390,685 | 7,101,170 |
| Revenue | 687,028 | 620,703 | 643,096 | 783,371 |
| EBITDA | (314,217) | (335,508) | 1,513,885 | (4,085,710) |
| Net Income | (376,547) | (399,236) | 1,226,235 | (4,499,434) |
| Total Assets | 2,010,994 | 2,190,332 | 2,518,671 | 5,127,977 |
| Total Debt | 34,660 | 38,245 | 32,206 | 4,784,648 |
Kangmei Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kangmei Pharmaceutical Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Ma Xingtian | Chairman |
Kangmei Pharmaceutical Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00 00000000 | Kangmei Pharmaceutical | Chairman | 000 0000 |
Kangmei Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kangmei Pharmaceutical Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 02-Apr-2018 | 00000 0000 | 00000 | Drug Discovery | |
| Guangzhou Bingchi Medical Technology Development | 27-Jul-2017 | Merger/Acquisition | 00.000 | Diagnostic Equipment |
Kangmei Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 12, 2019
50.98 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 12,277
Rank
Percentile
Pharmaceuticals
Industry
00 of 709
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 340
Rank
Percentile
Kangmei Pharmaceutical Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000 0000000000 | 02-Apr-2018 | 00000 00000 00 | 00000 | Completed |
|